Contineum Therapeutics, a startup emerging from a Roche buyout, has filed for an Initial Public Offering (IPO) with plans to raise $150 million for phase 2 clinical trials of its lead prospect and a molecule developed in partnership with Johnson & Johnson. The company joins a growing list of biotech firms seeking to go public this year.
What once hot biotech of 2017 will have market moving data in Q2 2024? $AFMD $FGEN $GLYC Vote below or reply with a name that is currently left for dead from the past with imminent data. https://t.co/caY7Y6sNmx
Contineum Therapeutics has filed a $150 million IPO — adding to the growing list of biotechs with plans to go public this year. More in The Readout newsletter: https://t.co/XaeeKtBwjL
Contineum, a startup born from a Roche buyout, files for IPO https://t.co/wQ8Hs1Kj0K by @BentheFidler
Contineum Therapeutics filed IPO paperwork to raise money for phase 2 clinical trials of its lead prospect and a Johnson & Johnson-partnered molecule. https://t.co/gfoHBXaMSR
Contineum, a startup born from a Roche buyout, files for #IPO https://t.co/H1KfPNveym @VersantVentures $RHHBY $JNJ $BMY $GPCR